FDA approval is one of the big reasons biohealth startups often take longer to get off the ground than other categories, like software.
So when TEDCO took over a fund that specifically catered to the category amid last year’s reorganization, the state’s quasi-governmental investment arm decided to specifically target companies that needed some more runway as they sought the government-guarded milestone.
On Wednesday, TEDCO announced the first round of companies that will receive money from the Life Science Investment Fund, and three are from Baltimore. The $200,000 investments are made in the form a five-year convertible note.
Here’s who got funding:
- Sonavex, a Johns Hopkins spinout that makes a system to improve blood clot detection during surgeries.
- AsclepiX Therapeutics, a Johns Hopkins spinout developing pharmaceuticals that can replicate the body’s natural processes.
- Vasoptic Medical, a Locust Point-based company which is making a device that allows primary care doctors to give eye exams to diabetes patients, rather than an eye doctor.
- Gel-e, a College Park-based company that is commercializing hemostatic medical devices.
UMB licenses technology to Y Combinator-backed biotech startup
Introducing ‘Off the Sidelines,’ a new podcast series about startup investing
Investment gives Vista Equity Partners majority stake in Maryland’s Sonatype
How independence fuels confidence and professional development at SmartLogic
Illumina opens training center at the University of Maryland BioPark
This form of art blends science and technology to tell stories through biological products
Why Baltimore rose to the ‘top of the list’ when this biotech team needed a new HQ
How this lawyer is helping entrepreneurs bark up the right tree
Sign-up for daily news updates from Technical.ly Baltimore